Marksans Pharma acquires Dubai-based Access Healthcare for Rs 27 cr

Image
Capital Market
Last Updated : Apr 25 2022 | 12:50 PM IST

Marksans Pharma signed a share purchase agreement to acquire a 100% stake in Access Healthcare for Medical Products L.L.C, a Dubai-based front-marketing and promotion company for a cash consideration of AED 13 million.

This transaction was approved by the board of Marksans Pharma on 23 April 2022. The acquisition is expected to be completed by 30 June 2022. Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies innovative marketing and sales solutions in the MENA (Middle East & North Africa) region. The company supplies these products in the UAE and other neighboring countries.

In the UAE market, Marksans Pharma supplied products through the Dubai Health Authority (DHA). It has market authorizations by the UAE regulatory authorities for various products. For the year ended December 2021, Access Healthcare for Medical Products registered a revenue of AED 12 million (Rs 25 crore) and a profit after tax ofAED 4.5 million (Rs 9.40 crore). The company has no debt on its books.

As per the company's press release, this deal will enable the company to use the front-end sales and marketing infrastructure of Access Healthcare for marketing its products manufactured in the India, UK, and USA regions. It will bolster Marksans Pharma's presence in the Middle East and North African regions by leveraging Access Health's knowledge of local business cultures and access to a network of partners and distributors in those regions.

The shareholders of Access Healthcare will receive a cash consideration of AED 13 million (Rs 27.10 crore) on closure of the transaction, which is subject to regulatory approvals. The transaction will be funded from internal accruals, as per the company's exchange filing.

On a consolidated basis, the company reported a 18.1% fall in net profit to Rs 48.27 crore on a 1.2% rise in net sales to Rs 362.63 crore in Q3 FY22 over Q3 FY21.

Shares of Marksans Pharma shed 1.97% to Rs 54.70 on BSE. Marksans Pharma is an Indian pharmaceutical company having a global footprint. The company's strengths lie in research, manufacturing and marketing of finished dosage pharmaceutical formulations.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 25 2022 | 12:30 PM IST

Next Story